The purpose of this clinical study is to compare 2 different versions cagrilintide and see how these work in people living with excess body weight. Participant will get either cagrilintide B or cagrilintide D injections. Which treatment participant will get is decided by chance. Participant will be in this clinical study for about 14 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
Cagrilintide B will be administered subcutaneously.
Cagrilintide D will be administered subcutaneously.
Celerion, Phoenix
Tempe, Arizona, United States
AUCss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide
Measured as hour\*nanomole per liter (h\*nmol/L).
Time frame: From Pre-dose at Day 29 to Day 36
Cmax,ss: maximum observed concentration of total cagrilintide at steady state after 5th dosing of cagrilintide
Measured as nanomole per liter (nmol/L).
Time frame: From Pre-dose at Day 29 to Day 36
AUCss: area under the total cagrilintide concentration-time curve at steady state after 4th dosing of cagrilintide
Measured as h\*nmol/L.
Time frame: From Pre-dose at Day 22 to Day 29
Cmax,ss: maximum observed concentration of total cagrilintide at steady state after 4th dosing of cagrilintide
Measured as nmol/L.
Time frame: From Pre-dose at Day 22 to Day 29
AUCss: area under the total cagrilintide concentration-time curve at steady state after 1st dosing of cagrilintide
Measured as h\*nmol/L.
Time frame: From Pre-dose at Day 1 to Day 8
Cmax,ss: maximum observed concentration of total cagrilintide at steady state after 1st dosing of cagrilintide
Measured as nmol/L.
Time frame: From Pre-dose at Day 1 to Day 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.